Pimicotinib for tenosynovial giant cell tumour (MANEUVER)

Paglalarawan

A new phase 3 trial (MANEUVER) investigates pimicotinib, a highly selective CSF-1R inhibitor, for unresectable tenosynovial giant cell tumour (TGCT). Part 1 results show promising anti-tumor activity with a manageable safety profile. In this video, authors of the trial describe MANEUVER and explain what this could mean for TGCT patients. Read the full article at: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02602-9/fulltext?dgcid=youtube_video_lancet_maneuver-2026 Visit The Lancet at https://www.thelancet.com/?dgcid=youtube_video_lancet_maneuver-2026 * * * Continue this conversation on social! Follow us today at… https://TheLancet.bsky.social/ https://Facebook.com/TheLancetMedicalJournal https://Instagram.com/TheLancetGroup https://LinkedIn.com/company/The-Lancet